Literature DB >> 9445027

Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells.

M Paul1, S Mazumder, N Raja, M A Jabbar.   

Abstract

Human immunodeficiency virus type 1 Vpu is a multifunctional phosphoprotein composed of the N-terminal transmembrane (VpuTM) and C-terminal cytoplasmic domains. Each of these domains regulates a distinct function of the protein; the transmembrane domain is critical in virus release, and phosphorylation of the cytoplasmic domain is necessary for CD4 proteolysis. We carried our experiments to identify amino acids in the VpuTM domain that are important in the process of virus-like particle (VLP) release from HeLa cells. VLPs are released from the plasma membrane of HeLa cells at constitutive levels, and Vpu expression enhanced the release of VLPs by a factor of 10 to 15. Deletion of two to five amino acids from both N- and C-terminal ends or the middle of the VpuTM domain generated mutant Vpu proteins that have lost the ability to enhance VLP release. These deletion mutants have not lost the ability to associate with the wild-type or mutant Vpu proteins and formed complexes with equal efficiency. They were also transported normally to the Golgi complex. Furthermore, a Vpu protein having the CD4 transmembrane and Vpu cytoplasmic domains was completely inactive, and Vpu proteins harboring hybrid Vpu-CD4 TM domains were also defective in the ability to enhance the release of VLPs. When tested for functional complementation in cotransfected cells, two inactive proteins were not able to reconstitute Vpu activity that enhances the release of Gag particles. Coexpression of functional CD4/Vpu hybrids or wild-type Vpu with inactive mutant CD4/Vpu proteins revealed that mutations in the VpuTM domain could dominantly interfere with Vpu activity in Gag release. Taken together, these results demonstrated that the structural integrity of the VpuTM domain is critical for Vpu activity in the release of VLPs from the plasma membrane of mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445027      PMCID: PMC124605     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Ion channels as enzymes: analogy or homology?

Authors:  E Marban; G F Tomaselli
Journal:  Trends Neurosci       Date:  1997-04       Impact factor: 13.837

2.  Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4.

Authors:  M Paul; M A Jabbar
Journal:  Virology       Date:  1997-05-26       Impact factor: 3.616

3.  Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule.

Authors:  E Tiganos; X J Yao; J Friborg; N Daniel; E A Cohen
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  The active oligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer.

Authors:  T Sakaguchi; Q Tu; L H Pinto; R A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Characterization of human immunodeficiency virus type 1 Pr55gag membrane association in a cell-free system: requirement for a C-terminal domain.

Authors:  E J Platt; O K Haffar
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

6.  Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate.

Authors:  J W Balliet; D L Kolson; G Eiger; F M Kim; K A McGann; A Srinivasan; R Collman
Journal:  Virology       Date:  1994-05-01       Impact factor: 3.616

7.  Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein.

Authors:  J Friborg; A Ladha; H Göttlinger; W A Haseltine; E A Cohen
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-01-01

8.  The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?

Authors:  S Bour; U Schubert; K Peden; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains.

Authors:  U Schubert; S Bour; A V Ferrer-Montiel; M Montal; F Maldarell; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes.

Authors:  U Schubert; K A Clouse; K Strebel
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  23 in total

1.  Molecular dynamics simulations on the first two helices of Vpu from HIV-1.

Authors:  I Sramala; V Lemaitre; J D Faraldo-Gómez; S Vincent; A Watts; W B Fischer
Journal:  Biophys J       Date:  2003-05       Impact factor: 4.033

2.  Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.

Authors:  Raphaël Vigan; Stuart J D Neil
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

3.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Molecular dynamics simulation of human immunodeficiency virus protein U (Vpu) in lipid/water Langmuir monolayer.

Authors:  Feng Sun
Journal:  J Mol Model       Date:  2003-04-02       Impact factor: 1.810

5.  The vpu protein of human immunodeficiency virus type 1 plays a protective role against virus-induced apoptosis in primary CD4(+) T lymphocytes.

Authors:  Satoshi Komoto; Shoutaro Tsuji; Madiha S Ibrahim; Yong-Gang Li; Jiranan Warachit; Koki Taniguchi; Kazuyoshi Ikuta
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.

Authors:  Yukie Iwabu; Hideaki Fujita; Masanobu Kinomoto; Keiko Kaneko; Yukihito Ishizaka; Yoshitaka Tanaka; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

Review 7.  Human cellular restriction factors that target HIV-1 replication.

Authors:  Klaus Strebel; Jeremy Luban; Kuan-Teh Jeang
Journal:  BMC Med       Date:  2009-09-16       Impact factor: 8.775

8.  Viral replication is enhanced by an HIV-1 intersubtype recombination-derived Vpu protein.

Authors:  Cristian De Candia; Constanza Espada; Gabriel Duette; Yanina Ghiglione; Gabriela Turk; Horacio Salomón; Mauricio Carobene
Journal:  Virol J       Date:  2010-10-04       Impact factor: 4.099

9.  Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Authors:  Bin Jia; Ruth Serra-Moreno; William Neidermyer; Andrew Rahmberg; John Mackey; Ismael Ben Fofana; Welkin E Johnson; Susan Westmoreland; David T Evans
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

10.  The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.

Authors:  Amy J Andrew; Eri Miyagi; Sandra Kao; Klaus Strebel
Journal:  Retrovirology       Date:  2009-09-08       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.